论文部分内容阅读
心肌损伤生物标志物的检测在心脏疾病临床诊断上被广泛应用,但是在新药的非临床安全评价方面,心肌损伤标志物的应用相对滞后。目前中国、美国、经济合作发展组织(OECD)的新药安全评价指导原则推荐的检测心脏功能的指标为谷草转氨酶(AST)、乳酸脱氢酶(LDH)和肌酸激酶(CK)。但是上述指标敏感性差(如AST)以及存在同工酶(如LDH和CK),所以不能特异灵敏地反映心脏的功能。目前国际上高度推崇采用敏感效应生物标志物来监测心脏的靶器官毒性。近年来肌红蛋白(Mb)、脑型钠尿肽(BNP)、心肌肌钙蛋白(cTn)对心肌损伤的检测展现了良好的应用价值,本文将对上述3项国内外研究最热点的心肌损伤生物标志物进行阐述。
The detection of myocardial injury biomarkers is widely used in the clinical diagnosis of heart disease, but the application of myocardial injury markers lags behind in non-clinical safety evaluation of new drugs. At present, the indicators of cardiac function recommended by the guideline of new drug safety evaluation of China, the United States and the Organization for Economic Co-operation and Development (OECD) are aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK). However, these indicators of poor sensitivity (such as AST) and the presence of isoenzymes (such as LDH and CK), it can not specifically reflect the heart’s function. At present, highly sensitive biomarkers are highly recommended to monitor cardiac target organ toxicity. In recent years, myoglobin (Mb), brain natriuretic peptide (BNP), cardiac troponin (cTn) detection of myocardial injury has shown a good value, this article will study the three most hot spots at home and abroad myocardial Damage biomarkers are described.